Fluciclatide F-18 | MedKoo Biosciences

Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

Other drug agents

Drug intermediates

Bio-reagents and biochemicals

MedKoo product information:

Fluciclatide F-18

MedKoo Code#: 205460

Name: Fluciclatide F-18

CAS#: 879894-01-6

Synonym: [18F]AH111585. Other name:

(1). L-Cysteinamide, N6-[29-[4-(fluoro-18F)phenyl]-1,5,25-trioxo-3,9,12,15,18,21,27- heptaoxa-6,24,28-triazanonacos-28-en-1-yl]-N2-(2-mercaptoacetyl)-L-lysyl-L-cysteinyl- L-arginylglycyl-L-α-aspartyl-L-cysteinyl-L-phenylalanyl-N-(17-amino-13,17-dioxo- 3,6,9,15-tetraoxa-12-azaheptadec-1-yl)-, cyclic (1→8)-thioether, cyclic (2→6)-disulfide.

(2). 6-N-[(28E)-29-(4-[18F]fluorophenyl)-5,25-dioxo-3,9,12,15,18,21,27-heptaoxa-6,24,28- triazanonacos-28-enoyl]-2-N-(2-sulfanylacetyl)-L-lysyl-L-cysteinyl-L-arginylglycyl-L-α- aspartyl-L-cysteinyl-L-phenylalanyl-1-N-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa-12- azaheptadecyl)-L-cysteinamide cyclic (2→6)-disulfide cyclic (1→8)-thioether

　

IUPAC/Chemical name:

Chemical structure:

Theoretical analysis:

MOLECULAR FORMULA: C₇₅H₁₁₅¹⁸FN₁₈O₂₇S₃
MOLECULAR WEIGHT: 1815

Availability and price:

This agent is not in stock, which may be available through custom synthesis.

To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

Information about this agent

fluciclatide F 18 is a radiopharmaceutical compound of a small synthetic cyclic peptide containing an RGD-sequence (Arg-Gly-Asp) labeled with the positron-emitting isotope fluorine F 18 that may be used to selectively image tumor cells and tumor vasculature by PET imaging. The RGD motif of fluciclatide F 18 selectively binds to the alphaVbeta3 integrin receptor, commonly upregulated on the surfaces of tumor cells and endothelial cells of tumor vasculature. This agent may be of use in visualizing and quantifying the development of tumor vascularity in response to antiangiogenic agents. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Fluciclatide is a small cyclic peptide containing the RGD tri-peptide, which preferentially binds with high affinity to alpha(v)beta(3) integrins, which are up-regulated in and may regulate angiogenesis. [18F]Fluciclatide is a new radiopharmaceutical developed for PET imaging. Changes in [18F]fluciclatide uptake will be evaluated before and after treatment of patients with targeted antiangiogenic drugs.

Current developer: G. E. Healthcare, Inc.

References

1: Tomasi G, Kenny L, Mauri F, Turkheimer F, Aboagye EO. Quantification of receptor-ligand binding with [(18)F]fluciclatide in metastatic breast cancer patients. Eur J Nucl Med Mol Imaging. 2011 Sep 3. [Epub ahead of print] PubMed PMID: 21892622.

2: Battle MR, Goggi JL, Allen L, Barnett J, Morrison MS. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent. J Nucl Med. 2011 Mar;52(3):424-30. Epub 2011 Feb 14. PubMed PMID: 21321268.

3: Beer AJ, Schwaiger M. PET of αvbeta3-integrin and αvbeta5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time? J Nucl Med. 2011 Mar;52(3):335-7. Epub 2011 Feb 14. PubMed PMID: 21321266.

Contact MedKoo:

Email: sales@medkoo.com

(Keyword; CAS#; MedKoo code#)